Comparison Between ex Vivo and in Vivo Injection of Blue Dye in Sentinel Lymph Node Mapping for Colon Cancer

Status

UNKNOWN

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00654342

Enrollment

100

Registered

2008-04-08

Start date

2007-10-31

Completion date

Unknown

Last updated

2008-04-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Colon Cancer, Sentinel Lymph Node Biopsy

Keywords

Sentinel lymph node-colon cancer

Brief summary

The technique of sentinel lymph node mapping in patients with colon cancer varies among reports, and the optimal method remain to be established. The purpose of this study was to determine the optimal injection technique for sentinel lymph node mapping for colon cancer.

Interventions

PROCEDUREIntraoperative injection (in vivo)

Intraoperative injection

PROCEDUREPostoperative injection (ex vivo)

postoperative injection

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Masking

SINGLE (Subject)

Eligibility

Sex/Gender

ALL

Age

18 Years to 80 Years

Healthy volunteers

Inclusion criteria

* Stage I - III colon cancer patients

Exclusion criteria

* cancer located at the low rectum which were located within 10 cm of the dentate, recurrent or metastatic colon carcinoma, adjacent organ invasion tumor, prior chemotherapy or radiation, cancer with intestinal obstruction, past intestinal surgery

Design outcomes

Primary

Measure	Time frame
Accuracy & sensitivity of sentinel lymph node mapping	After confirmed pathological report

Countries

South Korea

Contacts

Primary ContactIn-Taik Chang, M.D., Ph.D.

caumed5@naver.com82-2-6299-1562

Backup ContactJun Seok Park, M.D.

doctorsupreme@gmail.com82-2-6299-1548

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026